B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21

International Immunology

Volumn 26, Issue 7, 2014, Pages 383-395

  Hagn, Magdalena ^a   Blackwell, Sue E ^b   Beyer, Thamara ^c   Ebel, Verena ^d   Fabricius, Dorit ^e   Lindner, Stefanie ^c   Stilgenbauer, Stefan ^f   Simmet, Thomas ^d   Tam, Constantine ^a   Neeson, Paul ^a   Trapani, Joseph A ^a   Schrezenmeier, Hubert ^c   Weiner, George J ^b   Jahrsdörfer, Bernd ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF IOWA   (United States)

^c German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^d Institute of Pharmacology of Natural Products and Clinical Pharmacology   (Germany)

^e Department of Pediatrics ^*  (Germany)

^f UNIVERSITY OF ULM   (Germany)

Author keywords

Cross presentation; Cytotoxic B cells; Immunogenization; Leukemia vaccine; Toll like receptor agonist

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; INTERLEUKIN 21; PERFORIN; SERINE PROTEINASE INHIBITOR; CPG-OLIGONUCLEOTIDE; CXCL10 PROTEIN, HUMAN; GRANZYME; INTERLEUKIN DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT PROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; AGED; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; B-CELL LEUKEMIA CELL LINE; CANCER IMMUNOTHERAPY; CELL STIMULATION; CELL STRUCTURE; CELL SURVIVAL; CLINICAL ARTICLE; CROSS PRESENTATION; CYTOGENETICS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; APOPTOSIS; B-LYMPHOCYTES; CHEMOKINE CXCL10; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GRANZYMES; HUMANS; IMMUNOPHENOTYPING; INTERLEUKINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PERFORIN; PRIMARY CELL CULTURE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS;

EID: 84903638481     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu001     Document Type: Article

References (49)

1. O'Brien, S., del Giglio, A. and Keating, M. 1995. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85:307.
2. Jahrsdörfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Link, B. K. and Weiner, G. J. 2005. Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia 19:759.
3. Longo, P. G., Laurenti, L., Gobessi, S. et al. 2007. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21:110.
4. Rezvany, M. R., Jeddi-Tehrani, M., Rabbani, H. et al. 2000. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br. J. Haematol. 111:608.
5. Kollgaard, T., Petersen, S. L., Hadrup, S. R. et al. 2005. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 19:2273.
6. Kokhaei, P., Rezvany, M. R., Virving, L. et al. 2003. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 17:894.
7. Hus, I., Rolinski, J., Tabarkiewicz, J. et al. 2005. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19:1621.
8. Jahrsdörfer, B., Hartmann, G., Racila, E. et al. 2001. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69:81.
9. Wierda, W. G., Cantwell, M. J., Woods, S. J., Rassenti, L. Z., Prussak, C. E. and Kipps, T. J. 2000. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96:2917.
10. Jahrsdorfer, B., Mühlenhoff, L., Blackwell, S. E. et al. 2005. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 11:1490.
11. Jahrsdörfer, B., Wooldridge, J. E., Blackwell, S. E. et al. 2005. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 77:378.
12. Jahrsdörfer, B., Blackwell, S. E., Wooldridge, J. E. et al. 2006. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 108:2712.
13. Zent, C. S., Smith, B. J., Ballas, Z. K. et al. 2012. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk. Lymphoma 53:211.
14. Kolb, J. P. 2008. IL-21 as new therapy for CLL? Blood 111:4424.
15. Parrish-Novak, J., Dillon, S. R., Nelson, A. et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57.
16. Jin, H., Carrio, R., Yu, A. and Malek, T. R. 2004. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173:657.
17. Gowda, A., Roda, J., Hussain, S. R. et al. 2008. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111:4723.
18. Hagn, M., Schwesinger, E., Ebel, V. et al. 2009. Human B cells secrete granzyme B when recognizing viral antigens in the context of the acute phase cytokine IL-21. J. Immunol. 183:1838.
19. Hagn, M., Ebel, V., Sontheimer, K. et al. 2010. CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B. Eur. J. Immunol. 40:2060.
20. Konforte, D., Simard, N. and Paige, C. J. 2009. IL-21: an executor of B cell fate. J. Immunol. 182:1781.
21. Glimcher, L. H., Townsend, M. J., Sullivan, B. M. and Lord, G. M. 2004. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4:900.
22. Catalfamo, M. and Henkart, P. A. 2003. Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol. 15:522.
23. Trapani, J. A. and Sutton, V. R. 2003. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15:533.
24. Jones, D., Benjamin, R. J., Shahsafaei, A. and Dorfman, D. M. 2000. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 95:627.
25. Van den Hove, L. E., Van Gool, S. W., Vandenberghe, P. et al. 1997. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11:572.
26. Fabricius, D., Breckerbohm, L., Vollmer, A. et al. 2011. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia 25:1111.
27. Krackhardt, A. M., Harig, S., Witzens, M., Broderick, R., Barrett, P. and Gribben, J. G. 2002. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 100:167.
28. Ida, H., Nakashima, T., Kedersha, N. L. et al. 2003. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur. J. Immunol. 33:3284.
29. Gorak-Stolinska, P., Truman, J. P., Kemeny, D. M. and Noble, A. 2001. Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNFalpha. J. Leukoc. Biol. 70:756.
30. Davids, M. S. and Burger, J. A. 2012. Cell trafficking in chronic lymphocytic leukemia. Open J. Hematol. 3:pii.
31. Youinou, P. and Renaudineau, Y. 2007. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun. Rev. 7:149.
32. Bubier, J. A., Bennett, S. M., Sproule, T. J. et al. 2007. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1110:590.
33. Ghia, P., Scielzo, C., Frenquelli, M., Muzio, M. and Caligaris-Cappio, F. 2007. From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun. Rev. 7:127.
34. Zheng, Y., Manzotti, C. N., Liu, M., Burke, F., Mead, K. I. and Sansom, D. M. 2004. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J. Immunol. 172:2778.
35. Hoves, S., Sutton, V. R., Haynes, N. M. et al. 2011. A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J. Immunol. 187:1166.
36. Casciola-Rosen, L., Andrade, F., Ulanet, D., Wong, W. B. and Rosen, A. 1999. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J. Exp. Med. 190:815.
37. Jahrsdörfer, B., Vollmer, A., Blackwell, S. E. et al. 2010. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115:1156.
38. Korthals, M., Safaian, N., Kronenwett, R. et al. 2007. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J. Transl. Med. 5:46.
39. Di Pucchio, T., Chatterjee, B., Smed-Sörensen, A. et al. 2008. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat. Immunol. 9:551.
40. Spadaro, F., Lapenta, C., Donati, S. et al. 2012. IFN-a enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119:1407.
41. Chan, C. W., Crafton, E., Fan, H. N. et al. 2006. Interferonproducing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12:207.
42. Tel, J., Smits, E. L., Anguille, S., Joshi, R. N., Figdor, C. G. and de Vries, I. J. 2012. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 120:3936.
43. Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T. and Stingl, G. 2007. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204:1441.
44. Tesniere, A., Apetoh, L., Ghiringhelli, F. et al. 2008. Immunogenic cancer cell death: a key-lock paradigm. Curr. Opin. Immunol. 20:504.
45. Schnurr, M., Scholz, C., Rothenfusser, S. et al. 2002. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res. 62:2347.
46. Kokhaei, P., Choudhury, A., Mahdian, R. et al. 2004. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 18:1810.
47. Casciola-Rosen, L., Miagkov, A., Nagaraju, K. et al. 2008. Granzyme B: evidence for a role in the origin of myasthenia gravis. J. Neuroimmunol. 201-202:33.
48. Nierkens, S., den Brok, M. H., Garcia, Z. et al. 2011. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. 71:6428.
49. Andorsky, D. J. and Timmerman, J. M. 2008. Interleukin-21: biology and application to cancer therapy. Expert Opin. Biol. Ther. 8:1295.